Chu Janet N, Maselli Judith, Auerbach Andrew D, Fang Margaret C
Department of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Division of Hospital Medicine, University of California, San Francisco, San Francisco, CA, United States.
Thromb Res. 2017 Jul;155:65-71. doi: 10.1016/j.thromres.2017.04.012. Epub 2017 Apr 12.
Recent guidelines include aspirin as an option to prevent venous thromboembolism (VTE) in selected patients undergoing hip or knee replacement surgery. However, the efficacy of aspirin after arthroplasty has not been well-defined, particularly in more contemporary patient populations. We compared rates of post-operative VTE between patients who received aspirin-only versus anticoagulants after hip or knee arthroplasty, using data from a large US-based administrative database.
We conducted a retrospective cohort study of 231,780 adults who underwent total knee arthroplasty and 110,621 who underwent total hip arthroplasty in 2009-2012 and who received pharmacologic VTE prophylaxis (aspirin or anticoagulant) within the first 7days after surgery. We compared the risk of post-operative VTE between patients receiving aspirin-only vs. anticoagulants, controlling for clinical and hospital characteristics using multivariable logistic regression with propensity score adjustment.
Aspirin-only prophylaxis was administered to 7.5% of patients after knee arthroplasty and 8.0% after hip arthroplasty. Post-operative VTE was diagnosed in 2217 (0.96%) patients after knee arthroplasty and 454 (0.41%) after hip arthroplasty. Compared to anticoagulants, aspirin was not associated with a higher risk for post-operative VTE either after knee arthroplasty (adjusted odds ratio and 95% confidence interval [OR] 0.34 [0.24-0.48]) or hip arthroplasty (OR 0.82 [0.45-1.51]).
Aspirin was uncommonly administered as the sole prophylactic agent after hip or knee arthroplasty in this study. However, patients who received aspirin-only had similar rates of post-operative VTE compared to patients who received anticoagulants. Further research should focus on distinguishing which patients benefit more from anticoagulants versus aspirin after arthroplasty.
近期指南将阿司匹林列为接受髋或膝关节置换手术的特定患者预防静脉血栓栓塞(VTE)的一种选择。然而,关节置换术后阿司匹林的疗效尚未明确界定,尤其是在更现代的患者群体中。我们使用来自美国一个大型管理数据库的数据,比较了髋或膝关节置换术后仅接受阿司匹林治疗的患者与接受抗凝剂治疗的患者的术后VTE发生率。
我们对2009年至2012年接受全膝关节置换术的231,780名成年人以及接受全髋关节置换术的110,621名成年人进行了一项回顾性队列研究,这些患者在手术后的前7天内接受了药物性VTE预防(阿司匹林或抗凝剂)。我们比较了仅接受阿司匹林治疗的患者与接受抗凝剂治疗的患者的术后VTE风险,并使用倾向评分调整的多变量逻辑回归控制临床和医院特征。
膝关节置换术后7.5%的患者和髋关节置换术后8.0%的患者仅接受阿司匹林预防。膝关节置换术后2217名(0.96%)患者和髋关节置换术后454名(0.41%)患者被诊断为术后VTE。与抗凝剂相比,阿司匹林在膝关节置换术后(调整后的优势比和95%置信区间[OR]为0.34[0.24 - 0.48])或髋关节置换术后(OR为0.82[0.45 - 1.51])与术后VTE风险较高无关。
在本研究中,阿司匹林很少作为髋或膝关节置换术后的唯一预防药物使用。然而,仅接受阿司匹林治疗的患者与接受抗凝剂治疗的患者术后VTE发生率相似。进一步的研究应集中于区分关节置换术后哪些患者从抗凝剂与阿司匹林中获益更多。